Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 290, Issue 5, 2006, Pages

  Reddy, Janardan K ^a   Rao, M Sambasiva ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Nonalcoholic fatty liver disease; Obesity; Peroxisome proliferator activated receptors; Steatohepatitis

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ALCOHOLIC FATTY LIVER; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; ENERGY CONSUMPTION; FATTY ACID OXIDATION; HEPATITIS; HISTOLOGY; HUMAN; LIPID METABOLISM; LIPIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

FATTY ACIDS; FATTY LIVER; HUMANS; INFLAMMATION; LIPID METABOLISM; LIVER; MODELS, BIOLOGICAL; OXIDATION-REDUCTION;

EID: 33645828659     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00521.2005     Document Type: Review

References (25)

1. Adams LA, Angulo P, and Lindor KD. Nonalcoholic fatty liver disease. CMAJ 172: 899-905, 2005.
2. Adams LA, Lymp JF, Sauver JS, Sandeson SO, Lindor KD, Feldstein A, and Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121, 2005.
3. Browning JD and Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152, 2004.
4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, and Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395, 2004.
5. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Palolis P, Capussotti L, Salizzoni M, and Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocelllar carcinoma. Gastroenterology 123: 134-140, 2002.
6. Crabb DW, Galli A, Fischer M, and You M. Molecular mechanisms of alcohol fatty liver: role of peroxisome proliferator-activated receptor α. Alcohol 34: 35-38, 2004.
7. Day CP and James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998.
8. Evans RM, Barish GD, and Wang YX. PPARs and the complex journey to obesity. Nat Med 10: 1-7, 2004.
9. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, and Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 273: 15639-15645, 1998.
10. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, and Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143: 722-728, 2005.
11. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, and Rao MS. Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis. J Biol Chem 275: 28918-28928, 2000.
12. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, and Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113: 1774-1783, 2004.
13. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, and Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38: 123-132, 2003.
14. Kashireddy P and Rao MS. Lack of peroxisome proliferator-activated receptor α enhances methionine and choline deficient diet-induced steatohepatitis. Hep Res 30: 104-110, 2004.
15. Ludwig J, Viggiano TR, McGill DB, and Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980.
16. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, and Gonzalez FJ. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111: 737-747, 2003.
17. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, and Aoyama T. Peroxisome proliferator-activated receptor-α protects against alcohol-induced liver damage. Hepatology 40: 972-980, 2004.
18. Rao MS, and Kashireddy P, Musunuri S, and Okonkwo A. Prevention/reversal of chorine deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor α ligand in rats. In Vivo 16: 145-152, 2002.
19. Rao MS and Reddy JK. PPARα in the pathogenesis of fatty liver disease. Hepatology 40: 783-786, 2004.
20. Reddy JK and Hashimoto T. Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system. Annu Rev Nutr 21: 193-230, 2001.
21. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, and Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42: 641-649, 2005.
22. Tolwani RJ, Hamm DA, Tian L, Sharer JD, Vockley J, Rinaldo P, Matern D, Schoeb T, and Wood RA. Medium chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. Plos Genetics 1: 205-212, 2005.
23. Yanagitani A, Yamada Yasui Shimomura T, Murai R, Murawaki Y, Hashiguchi K, Kanbe T, Saeki T, Ichiba M, Tanabe Y, Yoshida Y, Morino SI, Kurimasa A, Usuda N, Yamazaki H, Kunisada T, Ito H, Murawaki Y, and Shiota G. Retinoic acid receptor dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 40: 366-375, 2004.
24. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, and Reddy JK. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J Biol Chem 278: 498-505, 2003.
25. Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch 444: 3-12, 2004.